At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KTTA Pasithea Therapeutics Corp.
Post-Mkt 05-20 19:28:57 EDT
0.7220
+0.0194
+2.76%
盘后0.7220
+0.00000.00%
16:10 EDT
High0.7420Low0.6973Vol248.51K
Open0.7197D1 Closing0.7026Amplitude6.36%
Mkt Cap24.13MTradable Cap7.37MTotal Shares33.41M
T/O178.94KT/O Rate2.44%Tradable Shares10.20M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate
Benzinga  ·  05-16
Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate
Pasithea Therapeutics Corp reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-16
Pasithea Therapeutics Corp reports results for the quarter ended March 31 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Reuters  ·  05-16
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Pasithea net loss narrows 19.5% to $2.87 million in Q1 2026
Reuters  ·  05-16
Pasithea net loss narrows 19.5% to $2.87 million in Q1 2026
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Reuters  ·  05-12
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan
Reuters  ·  05-06
Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
TIPRANKS  ·  05-05
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
Pasithea Therapeutics names Kartik Krishnan chief medical officer
Reuters  ·  05-04
Pasithea Therapeutics names Kartik Krishnan chief medical officer
Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones  ·  04-21
Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
GlobeNewswire  ·  04-20
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP
Reuters  ·  04-18
Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP
Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  04-03
Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
GlobeNewswire  ·  04-01
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Reuters  ·  04-01
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock
Simply Wall St.  ·  03-25
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock
Pasithea Therapeutics Corp expected to post a loss of 18 cents a share - Earnings Preview
Reuters  ·  03-21
Pasithea Therapeutics Corp expected to post a loss of 18 cents a share - Earnings Preview
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice
TIPRANKS  ·  02-21
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice
Nasdaq flags Pasithea Therapeutics for failing $1 minimum bid rule
Reuters  ·  02-21
Nasdaq flags Pasithea Therapeutics for failing $1 minimum bid rule
Pasithea Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
Reuters  ·  02-17
Pasithea Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
Pasithea Therapeutics Corporation Held Special Shareholder Meeting
Reuters  ·  01-29
Pasithea Therapeutics Corporation Held Special Shareholder Meeting

Introduction

Company Name.
Pasithea Therapeutics Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Issue price:
--